GEOVAX LABS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GEOVAX LABS, INC. (GOVX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $148.75 thousand for the 3-month period ending 2026-06-30, per its S-1 filed 2026-09-17.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-09-17
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $148.75K, a 49.19% decline year-over-year.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $206.82K, a 29.35% decline year-over-year.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $277.55K, a 113.62% increase year-over-year.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $292.74K, a 188.02% increase year-over-year.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $855.12K, a 10.57% increase from fiscal 2022.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $773.38K, a 187.05% increase from fiscal 2021.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $269.43K, a 1338.48% increase from fiscal 2020.
- GEOVAX LABS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $18.73K, a 82.06% decline from fiscal 2019.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 15 month |
|---|---|---|---|---|---|
| 2026-06-30 | $148.75K S-1 · filed 2026-09-17 | $355.56K derived: sum of 2 quarters · filed 2026-09-17 | |||
| 2026-03-31 | $206.82K S-1 · filed 2026-09-17 | ||||
| 2025-12-31 | $1.11M S-1 · filed 2026-09-17 | ||||
| 2025-09-30 | $277.55K 10-Q · filed 2025-11-13 | $570.29K derived: sum of 2 quarters · filed 2026-09-17 | $863.03K derived: sum of 3 quarters · filed 2026-09-17 | ||
| 2025-06-30 | $292.74K S-1 · filed 2026-09-17 | $585.48K derived: sum of 2 quarters · filed 2026-09-17 | |||
| 2025-03-31 | $292.74K S-1 · filed 2026-09-17 | ||||
| 2024-12-31 | $474.48K S-1 · filed 2026-09-17 | ||||
| 2024-09-30 | $129.92K 10-Q · filed 2025-11-13 | $231.56K derived: sum of 2 quarters · filed 2025-11-13 | $335.13K derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $101.64K 10-Q · filed 2025-11-13 | $205.21K derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $103.57K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $855.12K 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $227.11K 10-Q · filed 2024-11-12 | $453.13K derived: sum of 2 quarters · filed 2024-11-12 | $681.17K derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $226.01K 10-Q · filed 2024-11-12 | $454.05K derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $228.04K 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $773.38K 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | $190.19K 10-Q · filed 2023-11-08 | $380.38K derived: sum of 2 quarters · filed 2023-11-08 | $570.57K derived: sum of 3 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $190.19K 10-Q · filed 2023-11-08 | $380.38K derived: sum of 2 quarters · filed 2023-11-08 | |||
| 2022-03-31 | $190.19K 10-Q · filed 2023-11-08 | ||||
| 2021-12-31 | $269.43K 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | $56.19K 10-Q · filed 2022-11-09 | $56.19K 10-Q · filed 2021-11-12 | $168.57K derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $56.19K 10-Q · filed 2022-11-09 | $112.38K derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $56.19K 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $18.73K 10-K · filed 2022-03-09 | ||||
| 2020-03-31 | -$77.77K derived: 10-Q 15 month − 10-K 12 month · filed 2020-11-05 | $26.65K 10-Q · filed 2020-11-05 | |||
| 2019-12-31 | $104.42K 10-K · filed 2021-03-23 | ||||
| 2019-09-30 | $26.35K 10-Q · filed 2020-11-05 | $53.01K derived: sum of 2 quarters · filed 2020-11-05 | $79.66K derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $26.66K 10-Q · filed 2020-11-05 | $53.32K derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $26.65K 10-Q · filed 2020-08-10 | ||||
| 2018-12-31 | $155.30K 10-K · filed 2020-03-24 | ||||
| 2018-09-30 | $85.37K 10-Q · filed 2019-11-07 | $108.59K derived: sum of 2 quarters · filed 2019-11-07 | $132.57K derived: sum of 3 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $23.22K 10-Q · filed 2019-11-07 | $47.20K derived: sum of 2 quarters · filed 2019-11-07 | |||
| 2018-03-31 | $23.98K 10-Q · filed 2019-11-07 | ||||
| 2017-12-31 | $57.22K 10-K · filed 2019-03-26 | ||||
| 2016-12-31 | $967.67K 10-K · filed 2019-03-26 | ||||
| 2015-12-31 | $67.91K 10-K · filed 2018-03-23 | ||||
| 2014-12-31 | $379.10K 10-K · filed 2017-03-24 | ||||
| 2013-12-31 | $381.60K 10-K · filed 2016-03-16 | ||||
| 2012-12-31 | $310.08K 10-K · filed 2015-03-20 | ||||
| 2007-12-31 | $1.52M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |